［1］New NRCU, Disease TO. Toward precision medicine: building a knowledge network for biomedical research and a new mxonomy of disease［M］. Washington, DC: National Academies Press (US), 2011.

［2］SAADATIAN-ELAHI M, SLIMANI N, CHAJES V, et al. Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the european prospective investigation into cancer and nutrition［J］. AmJClin Nutr, 2009, 89 (1): 331-346.

［3］LIU Y, GAO G, YANG C, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus［J］. Int J MolSci, 2014, 15 (6): 10567-10577.

［4］RUIZ-GARCIA E, SCOTT V, MACHAVOINE C, et al. Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening［J］. Br JCancer, 2010, 102 (3): 462-468.

［5］WEN J, SONG C, JIANG D, et al. Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms and their interactions in hepatocellular carcinoma: a multi-centre case-control study［J］. Sci Rep, 2015, 5: 16489-16499.

［6］DEARAUJO TVB, RODRIGUES LC, DE ALENCARXIMENES RA, et al. Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study［J］. Lancet Infect Dis, 2016, 16 (12): 1356-1363.

［7］DEARAUJO TVB, XIMENES RAA, MIRANDA-FILHO DB, et al. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study［J］. Lancet Infect Dis, 2017, 18 (3): 328-336.

［8］KUCHENBACCKER KB, HOPPER JL, BARNES DR, et al. Risks of breast, ovarian, and contralateral breastcancer for BRCA1 and BRCA2 mutation carriers［J］. JAMA, 2017, 317 (23): 2402-2416.

［9］JAMAL-HANJANIi M, WILSON GA, MCGRANAHAN N, et al. Tracking the evolution of non-small-cell lung cancer［J］. N Engl J Med, 2017, 376 (22): 2109-2121.

［10］FANIDI A, MULLER DC, YUAN JM, et al. Circulating Folate, Vitamin B6, and Methionine in Relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3) ［J］. J Natl Cancer Inst, 2018, 110 (1): 57-67.

［11］CHAJES V, ASSI N, BIESSY C, et al. A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study［J］. Ann Oncol, 2017, 28 (11): 2836-2842.

［12］AGNOLI C, GRIONI S, PALA V, et al. Biomarkers of inflammation and breast cancer risk: a case-control study nested in the EPIC-Varese cohort ［J］. Sci Rep, 2017, 7 (1): 12708.

［13］NA R, ZHENG SL, HAN M, et al. Germline mutations in ATM, and BRCA1/2, distinguish risk for lethal and indolent prostate cancer and are associated with early age at death［J］.Eur Urol, 2017, 71 (5): 740-747.

［14］SONG N, CHOI JY, SUNG H, et al. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: A case-case study［J］. Int J Cancer, 2014, 135 (3): 669-681.

［15］FOROUHI NG, KOULMAN A, SHARP SJ, et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study［J］. Lancet Diabetes Endocrinol, 2014, 2 (10): 810-818.

［16］SAEZ-LLORENS X, TRICOU V, YU D, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study［J］.Lancet Infect Dis, 2018, 18 (2): 162-170.

［17］LI H, CAI J, CHEN R, et al. Particulate matter exposure and stress hormone levels: A Randomized, Double-Blind, Crossover Trial of Air Purification［J］. Circulation, 2017, 136 (7): 618-627.

［18］ZHANG Y, ZHANG L, LI R, et al. Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility［J］. AnnOncol, 2017, 28 (7): 1625-1630.

［19］LAU E. Gene expression：You are not alone-cis and trans factors both contribute to ASE［J］. Nat Rev Genet，2015，16（2）：68-69.

［20］BUIL A, BROWN AA, LAPPALAINEN T, et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins［J］. Nat Genet, 2015, 47 (1): 88-91.

［21］ZHOU J, YUL, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virusrelated hepatocellular carcinoma［J］. JClin Oncol, 2011, 29 (36): 4781-4788.

［22］KESIMER M, FORD AA, CEPPE A, et al. Airway mucin concentration as a marker of chronic bronchitis［J］. New England Journal of Medicine, 2017, 377 (10): 911-922.

［23］SHAW AT, KIM TM, CRINO L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial［J］. Lancet Oncol, 2017, 18 (7): 874-886.

［24］WANG H, ZHAO Y, ZHANG C, et al. Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas［J］.PLoS One, 2014, 9 (2): e89782.

［25］TSAIPC, BELLJT. Power and sample size estimation for epigenome-wide association scans to detect differential DNA methylation［J］. Int JEpidemiol, 2015, 44 (4): 1429-1441.

［26］SCHULTE PA, PERERA FP. Molecular epidemiology：principles and practices［M］.New York：Acedemic Press，1993.

［27］MCMICHAEL AJ. Invited commentary—“molecular epidemiology”：new pathway or new travelling companion［J］. Am JEpidemiol，1994，140（1）：1-11.

［28］KHOURY MJ, STEWART W, BEATY TH. The effect of genetic susceptibility on causal inference in epidemiologic studies［J］. Am JEpidemiol, 1987, 126 (4): 561-567.

［29］KHOURY MJ, BEATY TH, FLANDERS WD. Epidemiologic approaches to the use of DNA markers in the search for disease susceptibility genes［J］. EpidemioloRev, 1990, 12 (1): 41-55.

［30］SCHULTE PA. Methodologic issues in the use of biologic markers in epidemiologic research ［J］. Am JEpidemiol，1987，126（6）：1006-1016.

［31］WINN DM, REICHMAN ME, GUNTER E. Epidemiologic issues in the design and use of biologic specimen banks［J］. Epidemiol Rev, 1990, 12 (1): 56-70.

［32］HWANG SJ, BEATY TH, LIANG KY, et al. Minimum sample size estimation to detect gene-environment interaction in case-control designs［J］. Am JEpidemiol, 1994, 140 (11): 1029-1037.

［33］徐德忠.分子流行病学［M］.北京：人民军医出版社，1998.

［34］王素萍.流行病学［M］.第3版.北京：中国协和医科大学出版社，2017.

［35］詹思延.流行病学［M］.第8版.北京：人民卫生出版社，2017.

［36］叶冬青.流行病学进展（第13卷）［M］.北京：人民卫生出版社，2017.